Sanofi Consumer Healthcare India Q2 profit rises 13% as EBITDA margin reaches 37.9%
Sanofi Consumer Healthcare India reported Q2 net profit of ₹68.8 crore, up 13.3% year on year. Revenue grew 6.7% to ₹235.7 crore, supported by 12% domestic-sales growth and product relaunches, while EBITDA rose 27.2%.
What happened
Sanofi Consumer Healthcare India’s Q2 profit rose 13.3% to ₹68.8 crore as domestic sales grew 12%, aided by product relaunches. Revenue rose 6.7%, while EBITDA
Key facts
- Q2 net profit ₹68.8 crore, up 13.3% YoY from ₹60.7 crore
- Q2 revenue from operations ₹235.7 crore, up 6.7% YoY from ₹220.9 crore
- Q2 EBITDA ₹89.3 crore, up 27.2% YoY from ₹70.2 crore
- Q2 EBITDA margin 37.9%, versus 31.8% a year earlier
- Q2 domestic sales up 12%
- Q2 export sales down 9%
- First-half revenue ₹464.9 crore, up 18% YoY
- First-half domestic sales up 14%
- First-half export sales up 27%
Why this matters
The combination of relaunched products, domestic-market momentum and exceptionally high margins makes Sanofi Consumer Healthcare India an attractive benchmark or potential partner in India’s consumer-health consolidation landscape.
What to watch
- Whether domestic-sales growth stays above overall revenue growth in the next two quarters.
- Sustainability of EBITDA margin near 38% versus sequential advertising, employee and trade-spend increases.
- Management commentary on the contribution, repeat purchase and distribution gains from product relaunches.
- Volume growth versus price/mix contribution, especially in key OTC categories.
- Competitive promotional activity and pricing from other consumer-healthcare and FMCG players.
- Any changes in input costs, regulatory requirements, channel inventory or pharmacy stockist terms.
- Increase marketing and pharmacy-channel investment behind relaunched and high-margin brands.
- Expand distribution beyond core urban markets and deepen e-commerce/quick-commerce availability.
- Prioritize premiumization, pack-price architecture and selective innovation to preserve gross-margin gains.
- Use higher cash generation to support launches, working-capital efficiency and potential portfolio bolt-ons.